Atomoxetine
A genotype here changes the dose, not the diagnosis. Nothing about ADHD is decided by a gene test, and the guideline is about exposure.
What this drug connects to
The genes involved
Atomoxetine is a non-stimulant used for ADHD, and CYP2D6 polymorphisms influence its metabolism and thereby both its efficacy and its safety. CPIC published dosing recommendations by CYP2D6 genotype in 2019. This is about how much drug a person is exposed to at a given dose; it is not a prediction of whether ADHD treatment will help, and no genotype is used to decide whether to treat.
CPIC Guideline for CYP2D6 Genotype and Atomoxetine Therapy (Clin Pharmacol Ther 2019, PMID 30801677).
Whose work this rests on
Every guideline above was written by people. Named here because they are contributors to this page in the same sense anybody else on this site is.
Questions about Atomoxetine
What is atomoxetine?
Atomoxetine is a non-stimulant medicine used for ADHD. CYP2D6 polymorphisms influence its metabolism and thereby both its efficacy and its safety at a given dose.
Does CYP2D6 genotype decide whether I should be treated for ADHD with atomoxetine?
No. No genotype is used to decide whether to treat ADHD. CYP2D6 genotype is about how much atomoxetine a person is exposed to at a given dose, which is why CPIC published dosing recommendations by genotype in 2019.
What does CYP2D6 status actually change for atomoxetine, if not the diagnosis?
The dose. CYP2D6 polymorphisms influence atomoxetine’s metabolism and thereby both its efficacy and its safety at a given dose, and the clinician managing treatment uses this as one input.
Quoting this page
Licensed CC BY-NC 4.0: free to read, share and adapt for non-commercial use, naming MyGeneLog™ and linking the exact page. Commercial use, including training or serving a commercial AI system, needs a licence — https://www.mygenelog.com/license
Atomoxetine. MyGeneLog™. https://www.mygenelog.com/drugs/atomoxetine